{"event":{"category":"Financials","collateral_return_type":"MECNET","event_ticker":"KXSAROGLITAZAR-27","exchange_index":0,"last_updated_ts":"2026-10-28T07:26:31.622912Z","mutually_exclusive":true,"series_ticker":"KXSAROGLITAZAR","settlement_sources":[{"name":"AppliedXL","url":"https://www.appliedxl.com/"}],"strike_period":"","sub_title":"FDA decision on Saroglitazar in 2026","title":"FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)"},"markets":[{"can_close_early":true,"close_time":"2027-01-01T04:59:00Z","created_time":"2026-06-17T20:28:47.305048Z","early_close_condition":"This market will close early if the FDA issues a decision on Saroglitazar before Jan 1, 2027","event_ticker":"KXSAROGLITAZAR-27","exchange_index":0,"expected_expiration_time":"2027-01-01T15:00:00Z","expiration_value":"","last_price_dollars":"0.7900","latest_expiration_time":"2027-01-08T15:00:00Z","market_type":"binary","no_ask_dollars":"0.2800","no_bid_dollars":"0.2100","no_sub_title":"a full approval or an accelerated approval","notional_value_dollars":"1.0000","occurrence_datetime":"2027-01-01T15:00:00Z","open_interest_fp":"1151.90","open_time":"2026-06-17T21:30:00Z","previous_price_dollars":"0.7900","previous_yes_ask_dollars":"0.7900","previous_yes_bid_dollars":"0.7100","price_level_structure":"linear_cent","price_ranges":[{"end":"1.0000","start":"0.0000","step":"0.0100"}],"result":"","rules_primary":"If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.","rules_secondary":"This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nSaroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications.","settlement_bounds_type":"default","settlement_timer_seconds":1800,"status":"active","ticker":"KXSAROGLITAZAR-27-Y","title":"What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?","updated_time":"2026-10-16T07:41:23.805683Z","volume_24h_fp":"0.00","volume_fp":"1842.18","yes_ask_dollars":"0.7900","yes_ask_size_fp":"500.00","yes_bid_dollars":"0.7200","yes_bid_size_fp":"5.00","yes_sub_title":"a full approval or an accelerated approval"}]}
